Showing 2696 results for "amyotrophic lateral sclerosis (ALS)"

EMA recommends NUZ-001 for orphan drug status in Europe

The European Medicines Agency (EMA) has recommended that monepantel, now named NUZ-001, be granted orphan medicinal product designation to treat amyotrophic lateral sclerosis (ALS). The positive opinion will be reviewed by the European Commission, which is expected to issue a final decision in December. If granted, the designation will provide…

GM604 for ALS

GM604 is an experimental therapy designed to slow disease progression in people with ALS. It was developed by Genervon to be given via injections into the bloodstream. While positive results were seen in a Phase 2a trial, its current development status is unknown.

Research grant provides $7.3M for NU-9 development

Researchers at Northwestern University received a $7.3 million research grant from the National Institute on Aging to expand their work on NU-9, which has shown promise in amyotrophic lateral sclerosis (ALS) preclinical studies, and explore its effectiveness in other neurodegenerative diseases. The institute is a division of the National…